Related Experiment Videos
Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents
1Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA 19107.
Clinical Pharmacy
|November 1, 1987
Summary
Encainide hydrochloride and flecainide acetate are class 1c antiarrhythmic drugs effective for ventricular and supraventricular arrhythmias. Caution is advised due to potential proarrhythmic effects, especially in severe cases.
Area of Science:
- Pharmacology
- Clinical Cardiology
Background:
- Encainide hydrochloride and flecainide acetate are class 1c antiarrhythmic agents.
- These drugs slow myocardial conduction and prolong repolarization, affecting accessory pathway conduction.
Purpose of the Study:
- To review the chemistry, electrophysiology, pharmacokinetics, clinical use, efficacy, adverse effects, drug interactions, and dosage of encainide and flecainide.
- To evaluate their potential as therapeutic options for various arrhythmias.
Main Methods:
- Review of existing literature on encainide hydrochloride and flecainide acetate.
- Analysis of pharmacokinetic data, including bioavailability and metabolism.
- Assessment of clinical efficacy and adverse event profiles.
Main Results:
- Both encainide and flecainide demonstrate efficacy in suppressing ventricular arrhythmias and may help control supraventricular arrhythmias.
- Bioavailability varies significantly (encainide 7-82%, flecainide 90-95%).
- Central nervous system adverse effects like dizziness and blurred vision are common; proarrhythmic potential is a concern.
Conclusions:
- Encainide and flecainide are effective class 1c antiarrhythmic agents for managing various arrhythmias.
- Dosage adjustments may be necessary, particularly for flecainide in renal dysfunction.
- Careful patient selection and monitoring are crucial due to potential proarrhythmic risks.